Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.03
BSX's Cash-to-Debt is ranked lower than
96% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 2.54 vs. BSX: 0.03 )
Ranked among companies with meaningful Cash-to-Debt only.
BSX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.17 Max: N/A
Current: 0.03
Equity-to-Asset 0.39
BSX's Equity-to-Asset is ranked lower than
81% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. BSX: 0.39 )
Ranked among companies with meaningful Equity-to-Asset only.
BSX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.18  Med: 0.51 Max: 0.83
Current: 0.39
0.18
0.83
Interest Coverage 2.23
BSX's Interest Coverage is ranked lower than
92% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 73.23 vs. BSX: 2.23 )
Ranked among companies with meaningful Interest Coverage only.
BSX' s Interest Coverage Range Over the Past 10 Years
Min: 0.37  Med: 1.92 Max: 3.22
Current: 2.23
0.37
3.22
Piotroski F-Score: 6
Altman Z-Score: 1.98
Beneish M-Score: -2.54
WACC vs ROIC
7.49%
5.72%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 6.04
BSX's Operating Margin % is ranked higher than
58% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 3.45 vs. BSX: 6.04 )
Ranked among companies with meaningful Operating Margin % only.
BSX' s Operating Margin % Range Over the Past 10 Years
Min: -53.36  Med: -4.23 Max: 11.86
Current: 6.04
-53.36
11.86
Net Margin % 5.07
BSX's Net Margin % is ranked higher than
60% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.77 vs. BSX: 5.07 )
Ranked among companies with meaningful Net Margin % only.
BSX' s Net Margin % Range Over the Past 10 Years
Min: -56.12  Med: -4.56 Max: 5.79
Current: 5.07
-56.12
5.79
ROE % 6.60
BSX's ROE % is ranked higher than
61% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 2.13 vs. BSX: 6.60 )
Ranked among companies with meaningful ROE % only.
BSX' s ROE % Range Over the Past 10 Years
Min: -44.65  Med: -3.5 Max: 6.6
Current: 6.6
-44.65
6.6
ROA % 2.44
BSX's ROA % is ranked higher than
58% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 0.49 vs. BSX: 2.44 )
Ranked among companies with meaningful ROA % only.
BSX' s ROA % Range Over the Past 10 Years
Min: -21.16  Med: -1.48 Max: 2.44
Current: 2.44
-21.16
2.44
ROC (Joel Greenblatt) % 28.98
BSX's ROC (Joel Greenblatt) % is ranked higher than
73% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 6.15 vs. BSX: 28.98 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BSX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -144.7  Med: -14.88 Max: 32.39
Current: 28.98
-144.7
32.39
3-Year Revenue Growth Rate 4.60
BSX's 3-Year Revenue Growth Rate is ranked lower than
51% of the 239 Companies
in the Global Medical Devices industry.

( Industry Median: 5.30 vs. BSX: 4.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BSX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -10.5  Med: 4.6 Max: 29
Current: 4.6
-10.5
29
3-Year EBITDA Growth Rate 14.70
BSX's 3-Year EBITDA Growth Rate is ranked higher than
59% of the 210 Companies
in the Global Medical Devices industry.

( Industry Median: 6.30 vs. BSX: 14.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BSX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -71.1  Med: 14.7 Max: 271.1
Current: 14.7
-71.1
271.1
GuruFocus has detected 2 Warning Signs with Boston Scientific Corp $BSX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BSX's 30-Y Financials

Financials (Next Earnings Date: 2017-07-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

BSX Guru Trades in Q2 2016

Paul Tudor Jones 33,994 sh (New)
Jim Simons 4,901,905 sh (+692.67%)
John Paulson 94,000 sh (+27.03%)
Eaton Vance Worldwide Health Sciences Fund 3,880,000 sh (+12.46%)
PRIMECAP Management 42,640,450 sh (-1.65%)
Dodge & Cox 384,930 sh (-9.94%)
Mario Gabelli 687,746 sh (-13.60%)
Vanguard Health Care Fund 53,619,190 sh (-15.19%)
Pioneer Investments 2,962,863 sh (-21.76%)
Steven Cohen 1,915,982 sh (-28.12%)
Michael Price 900,000 sh (-48.28%)
Ray Dalio 9,684 sh (-73.24%)
Diamond Hill Capital 4,863,821 sh (-76.09%)
» More
Q3 2016

BSX Guru Trades in Q3 2016

Ray Dalio 50,900 sh (+425.61%)
John Paulson 410,000 sh (+336.17%)
Dodge & Cox 382,130 sh (-0.73%)
PRIMECAP Management 41,805,050 sh (-1.96%)
Mario Gabelli 673,046 sh (-2.14%)
Vanguard Health Care Fund 46,520,049 sh (-13.24%)
Steven Cohen 1,622,600 sh (-15.31%)
Paul Tudor Jones 26,610 sh (-21.72%)
Michael Price 700,000 sh (-22.22%)
Diamond Hill Capital 3,289,862 sh (-32.36%)
Pioneer Investments 1,878,761 sh (-36.59%)
Jim Simons 1,884,005 sh (-61.57%)
Eaton Vance Worldwide Health Sciences Fund 1,698,025 sh (-56.24%)
» More
Q4 2016

BSX Guru Trades in Q4 2016

Joel Greenblatt 99,384 sh (New)
David Tepper 550,000 sh (New)
Ray Dalio 91,000 sh (+78.78%)
Jim Simons 2,625,305 sh (+39.35%)
Pioneer Investments 1,941,017 sh (+3.31%)
Diamond Hill Capital 3,351,408 sh (+1.87%)
PRIMECAP Management 41,920,457 sh (+0.28%)
Michael Price 700,000 sh (unchged)
Steven Cohen 500,000 sh (unchged)
Paul Tudor Jones Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
Dodge & Cox 371,671 sh (-2.74%)
Mario Gabelli 653,146 sh (-2.96%)
Vanguard Health Care Fund 43,872,669 sh (-5.69%)
John Paulson 288,000 sh (-29.76%)
Steven Cohen 358,400 sh (-77.91%)
» More
Q1 2017

BSX Guru Trades in Q1 2017

Julian Robertson 900,000 sh (New)
Caxton Associates 20,100 sh (New)
Joel Greenblatt 1,664,082 sh (+1574.40%)
David Tepper 3,340,000 sh (+507.27%)
Jim Simons 5,726,705 sh (+118.13%)
Diamond Hill Capital 3,361,258 sh (+0.29%)
John Paulson Sold Out
Steven Cohen Sold Out
Ray Dalio Sold Out
Pioneer Investments 1,938,677 sh (-0.12%)
PRIMECAP Management 41,755,967 sh (-0.39%)
Vanguard Health Care Fund 42,272,393 sh (-3.65%)
Mario Gabelli 625,559 sh (-4.22%)
Dodge & Cox 328,655 sh (-11.57%)
Michael Price 500,000 sh (-28.57%)
» More
» Details

Insider Trades

Latest Guru Trades with BSX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:NAS:ISRG, NYSE:ZBH, NYSE:EW, NYSE:SYK, NAS:ALGN, NYSE:VAR, NYSE:TFX, NAS:ABMD, NAS:MASI, NAS:IART, NAS:NUVA, NYSE:GMED, NYSE:PEN, NYSE:NVRO, NAS:INGN, NAS:SPNC, NAS:MDXG, NAS:CNMD, NYSE:ITGR, NAS:BABY » details
Traded in other countries:BSX.Germany,
Headquarter Location:USA
Boston Scientific Corp is a developer, manufacturer and marketer of medical devices. The firm markets its devices to health-care professionals and institutions globally.

Boston Scientific produces less-invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract tests, and treatment of incontinence. The firm markets its devices to health-care professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Top Ranked Articles about Boston Scientific Corp

Boston Scientific Receives CE Mark for Vercise™ Gevia™ Deep Brain Stimulation System
Boston Scientific Announces Positive Outcomes From Prospective Study Of Bronchial Thermoplasty
The Boston Scientific LOTUS™ Valve System Demonstrated Superior Efficacy to CoreValve® in Global REPRISE III Trial at One Year
Julian Robertson Buys Adobe and Sells Apple in 1st Quarter Guru adds 3 positions and closes 3 others
Julian Robertson (Trades, Portfolio), founder of Tiger Management, invests with long-short strategies. During the first quarter, the guru added positions in Adobe Systems Inc. (NASDAQ:ADBE), Boston Scientific Corp. (NYSE:BSX) and JPMorgan Chase & Co. (NYSE:JPM). On the sell side, Robertson divested his holdings in HollyFrontier Corp. (NYSE:HFC), Apple Inc. (NASDAQ:AAPL) and Shire PLC (NASDAQ:SHPG). Read more...
Boston Scientific Announces Positive European Registry Results For WATCHMAN™ Left Atrial Appendage Closure Device
New Data from PLATINUM Diversity Study Presented at SCAI 2017 Provide Important Insights Beyond Traditional Clinically-Reported Endpoints
Boston Scientific S-ICD System Demonstrates Positive Clinical Outcomes in the Largest Prospective Study of 'Real-World' Patients
Boston Scientific Announces Schedule of Presentations at EuroPCR 2017
Boston Scientific Receives U.S. FDA Approval For Resonate™ Family Of High-Voltage Devices
Boston Scientific Announces Scheduled Presentations at Heart Rhythm Society 2017

Ratios

vs
industry
vs
history
PE Ratio 86.18
BSX's PE Ratio is ranked lower than
84% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 30.71 vs. BSX: 86.18 )
Ranked among companies with meaningful PE Ratio only.
BSX' s PE Ratio Range Over the Past 10 Years
Min: 13.87  Med: 39.61 Max: 404.33
Current: 86.18
13.87
404.33
Forward PE Ratio 22.08
BSX's Forward PE Ratio is ranked higher than
71% of the 49 Companies
in the Global Medical Devices industry.

( Industry Median: 25.64 vs. BSX: 22.08 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 86.18
BSX's PE Ratio without NRI is ranked lower than
84% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 31.10 vs. BSX: 86.18 )
Ranked among companies with meaningful PE Ratio without NRI only.
BSX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.87  Med: 39.61 Max: 404.33
Current: 86.18
13.87
404.33
Price-to-Owner-Earnings 50.89
BSX's Price-to-Owner-Earnings is ranked lower than
67% of the 109 Companies
in the Global Medical Devices industry.

( Industry Median: 36.31 vs. BSX: 50.89 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BSX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 11.58  Med: 45.99 Max: 985.26
Current: 50.89
11.58
985.26
PB Ratio 5.35
BSX's PB Ratio is ranked lower than
74% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 2.92 vs. BSX: 5.35 )
Ranked among companies with meaningful PB Ratio only.
BSX' s PB Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.44 Max: 5.45
Current: 5.35
0.59
5.45
PS Ratio 4.40
BSX's PS Ratio is ranked lower than
64% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 3.32 vs. BSX: 4.40 )
Ranked among companies with meaningful PS Ratio only.
BSX' s PS Ratio Range Over the Past 10 Years
Min: 1.02  Med: 2.22 Max: 4.49
Current: 4.4
1.02
4.49
Price-to-Free-Cash-Flow 69.66
BSX's Price-to-Free-Cash-Flow is ranked lower than
81% of the 110 Companies
in the Global Medical Devices industry.

( Industry Median: 32.13 vs. BSX: 69.66 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BSX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.21  Med: 20.75 Max: 220
Current: 69.66
7.21
220
Price-to-Operating-Cash-Flow 38.95
BSX's Price-to-Operating-Cash-Flow is ranked lower than
81% of the 135 Companies
in the Global Medical Devices industry.

( Industry Median: 19.50 vs. BSX: 38.95 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BSX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.75  Med: 15.91 Max: 62.72
Current: 38.95
5.75
62.72
EV-to-EBIT 88.74
BSX's EV-to-EBIT is ranked lower than
93% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 24.67 vs. BSX: 88.74 )
Ranked among companies with meaningful EV-to-EBIT only.
BSX' s EV-to-EBIT Range Over the Past 10 Years
Min: -2577.3  Med: -3.8 Max: 25838
Current: 88.74
-2577.3
25838
EV-to-EBITDA 41.60
BSX's EV-to-EBITDA is ranked lower than
86% of the 183 Companies
in the Global Medical Devices industry.

( Industry Median: 17.99 vs. BSX: 41.60 )
Ranked among companies with meaningful EV-to-EBITDA only.
BSX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -680.1  Med: 8.85 Max: 242.5
Current: 41.6
-680.1
242.5
Current Ratio 0.87
BSX's Current Ratio is ranked lower than
88% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 2.64 vs. BSX: 0.87 )
Ranked among companies with meaningful Current Ratio only.
BSX' s Current Ratio Range Over the Past 10 Years
Min: 0.52  Med: 1.56 Max: 7.77
Current: 0.87
0.52
7.77
Quick Ratio 0.59
BSX's Quick Ratio is ranked lower than
90% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. BSX: 0.59 )
Ranked among companies with meaningful Quick Ratio only.
BSX' s Quick Ratio Range Over the Past 10 Years
Min: 0.33  Med: 1.2 Max: 6.29
Current: 0.59
0.33
6.29
Days Inventory 143.75
BSX's Days Inventory is ranked lower than
55% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 128.08 vs. BSX: 143.75 )
Ranked among companies with meaningful Days Inventory only.
BSX' s Days Inventory Range Over the Past 10 Years
Min: 113.61  Med: 133.18 Max: 164.78
Current: 143.75
113.61
164.78
Days Sales Outstanding 60.78
BSX's Days Sales Outstanding is ranked higher than
60% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 68.17 vs. BSX: 60.78 )
Ranked among companies with meaningful Days Sales Outstanding only.
BSX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.51  Med: 61.98 Max: 66.79
Current: 60.78
58.51
66.79
Days Payable 54.85
BSX's Days Payable is ranked higher than
50% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 54.45 vs. BSX: 54.85 )
Ranked among companies with meaningful Days Payable only.
BSX' s Days Payable Range Over the Past 10 Years
Min: 21.66  Med: 35.22 Max: 67.31
Current: 54.85
21.66
67.31

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.00
BSX's 3-Year Average Share Buyback Ratio is ranked higher than
70% of the 226 Companies
in the Global Medical Devices industry.

( Industry Median: -4.10 vs. BSX: -1.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BSX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.9  Med: -1 Max: 4.6
Current: -1
-25.9
4.6

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.86
BSX's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
60% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 2.41 vs. BSX: 2.86 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BSX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.51  Med: 1.52 Max: 500
Current: 2.86
0.51
500
Price-to-Median-PS-Value 1.99
BSX's Price-to-Median-PS-Value is ranked lower than
87% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 1.01 vs. BSX: 1.99 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BSX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.48  Med: 1.47 Max: 4.29
Current: 1.99
0.48
4.29
Price-to-Peter-Lynch-Fair-Value 1.55
BSX's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 56 Companies
in the Global Medical Devices industry.

( Industry Median: 2.12 vs. BSX: 1.55 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
BSX' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0  Med: 1.63 Max: 12.18
Current: 1.55
0
12.18
Earnings Yield (Greenblatt) % 1.13
BSX's Earnings Yield (Greenblatt) % is ranked lower than
51% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 1.25 vs. BSX: 1.13 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BSX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -34.3  Med: -1.3 Max: 9.1
Current: 1.13
-34.3
9.1
Forward Rate of Return (Yacktman) % 42.39
BSX's Forward Rate of Return (Yacktman) % is ranked higher than
95% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 8.78 vs. BSX: 42.39 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BSX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 3.1  Med: 6.9 Max: 42.39
Current: 42.39
3.1
42.39

More Statistics

Revenue (TTM) (Mil) $8,582.00
EPS (TTM) $ 0.32
Beta0.94
Short Percentage of Float0.96%
52-Week Range $19.67 - 28.51
Shares Outstanding (Mil)1,369.40

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 8,867 9,409 10,029
EPS ($) 1.25 1.39 1.52
EPS without NRI ($) 1.25 1.39 1.52
EPS Growth Rate
(Future 3Y To 5Y Estimate)
12.68%
Dividends per Share ($)
» More Articles for BSX

Headlines

Articles On GuruFocus.com

More From Other Websites
Boston Scientific (BSX) Q2 Earnings: What Awaits the Stock? Jul 21 2017
Boston Scientific to Webcast Conference Call Discussing Second Quarter 2017 Financial Results Jul 05 2017
How Has Boston Scientific Stock Performed Recently? Jul 03 2017
ETFs with exposure to Boston Scientific Corp. : June 30, 2017 Jun 30 2017
How Boston Scientific’s Alair System Performed in Trials Jun 30 2017
How BSX’s Deep Brain Stimulation Portfolio Is Expanding Jun 30 2017
Boston Scientific Rides on New Growth Plans amid Headwinds Jun 30 2017
What Analysts Recommend for Boston Scientific Jun 30 2017
Top Stock Reports for Halliburton, Boston Scientific & Anheuser-Busch Jun 29 2017
Featured Company News - Boston Scientific Outlined Sustained Growth Strategy; Set to Expand into New... Jun 29 2017
Could Philips' Rivals Stage A Coup For Spectranetics? Jun 28 2017
Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day Jun 27 2017
Glassdoor: Apple CEO Tim Cook’s Employee Ranking Has Dropped Jun 21 2017
Boston Scientific Corp. :BSX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 Jun 16 2017
Boston Scientific Corporation -- Moody's assigns P-2 short term rating to Boston Scientific Jun 15 2017
Boston Scientific: We're always looking to add to portfol... Jun 15 2017
Why Boston Scientific Continues To Invest In Endoscopy Jun 13 2017
Boston Scientific Wins CE Mark for Vercise Gevia DBS System (revised) Jun 07 2017
Boston Scientific Receives CE Mark for Vercise™ Gevia™ Deep Brain Stimulation System Jun 06 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}